Treatment of orbital inflammation with rituximab in Wegener’s granulomatosis

B. Baslund¹, A.K. Wiencke², N. Rasmussen³, M. Faurschou¹, P.B. Toft⁴

¹Department of Rheumatology and Institute for Inflammatory Research, Institute for Inflammatory Research, Rigshospitalet, Copenhagen, Denmark; ²Department of Ophthalmology, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark; ³Department of Otorhinolaryngology, Head and Neck Surgery, and ⁴Department of Ophthalmology Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.

Bo Baslund, MD, PhD
Anne Katrine Wiencke, MD, PhD
Niels Rasmussen, MD
Mikkel Faurschou, MD, PhD
Peter Bjerre Toft, MD, DMSc

Please address correspondence to: Dr Bo Baslund,
Department of Rheumatology 4242,
Rigshospitalet,
9 Blegdamsvej,
DK-2100 Copenhagen, Denmark.
E-mail: bbslund@gmail.com
Received on March 22, 2011; accepted in revised form on June 21, 2011.
© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2012.

Key words: Wegener’s granulomatosis, orbital inflammation, rituximab

ABSTRACT

Objectives. To study the efficacy of rituximab therapy for the treatment of orbital inflammation in patients with Wegener’s granulomatosis (WG).

Methods. Ten WG patients with orbital inflammation were included in this case-series. None had symptoms suggestive of extra-orbital disease activity. Immunosuppressive medication (mycophenolate and prednisolone) was administered to 3 patients at the time of rituximab therapy. Three patients had previously been treated with anti-tumour-necrosis-factor-alpha antibodies, and one of these patients had also received cyclophosphamide as treatment for orbital inflammation. All patients were treated with 1000 mg of rituximab administered twice with an interval of 14 days between the infusions. Six months after therapy, a physical examination and a control computerised tomography (CT) scan was performed.

Results. All patients had orbital inflammation demonstrated by CT-scan before treatment (3 had bilateral and 7 unilateral orbital involvement). Orbital symptoms at study baseline included pain, pressure sensation behind the eyes, epiphora, diplopia, and affection of the visual acuity. Nine out of ten patients experienced subjective improvement. Four patients (seven eyes) with visual impairment responded to therapy, and the improvement in visual acuity was sustained throughout follow-up (median duration of follow-up: 17 months; range: 6–18 months). At the time of the control CT-scan, size-reduction of the orbital mass was observed in two patients, while the size of the orbital mass was unchanged in eight patients.

Conclusion. Rituximab therapy has positive effects on symptoms, visual acuity and/or granuloma size in some WG patients with orbital inflammation. Treatment with rituximab should be considered in WG patients with this serious manifestation of the disease.

Introduction

Wegener’s granulomatosis (WG) is an inflammatory condition characterised by granulomatous inflammation in the respiratory tract, necrotising vasculitis affecting small to medium-sized vessels, necrotising glomerulonephritis, and the presence of anti-neutrophil cytoplasmic auto-antibodies (ANCA) (1). Any organ system may be affected by the disease (2). Ophthalmic involvement is estimated to affect approximately 50% of WG patients, with clinical manifestations ranging from conjunctivitis and episcleritis to more severe inflammation with scleritis and retinal vasculitis (3). Orbital inflammation presenting as an orbital mass (orbital or retro-orbital pseudotumour/granuloma) can be detected in as many as 13% of patients with WG and is frequently associated with visual impairment (2). Orbital inflammation can occur without other organ manifestations during the course of WG, and may even be the presenting feature of the disease (4, 5). While depletion of CD20+ B cells is an effective treatment for WG patients with active vasculitis (6, 7) controversy exist as to the efficacy of anti-CD20-antibody therapy in patients with orbital disease (8-10). In this study, we used rituximab, a chimeric anti-CD20-antibody, for the treatment of ten WG patients with orbital inflammation and observed a high clinical response rate. Thus, our findings substantiate that anti-CD20 antibody therapy can be of benefit in WG patients with orbital disease involvement.

Patients and methods

From December 1, 2008, until November 31, 2009, all WG patients seen at our departments with orbital inflammation were included in the study. For patients to be considered eligible, a computerised tomography (CT)-scan should confirm the presence of an orbital mass. In total, 10 WG patients met this inclusion
Treatment of orbital inflammation with RTX in WG / B. Baslund et al.

Table I. Clinical characteristics of 10 patients with Wegener’s granulomatosis and orbital disease involvement at the time of rituximab therapy.

<table>
<thead>
<tr>
<th>Patient no./age/sex</th>
<th>Systemic organ involvement</th>
<th>Time from diagnosis to orbital inflammation (years)</th>
<th>Anti-TNF</th>
<th>AZA</th>
<th>MTX</th>
<th>CYC</th>
<th>MMF</th>
<th>Treatment at the time of RTX therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/61/M</td>
<td>ENT</td>
<td>2</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2/66/F</td>
<td>ENT, kidney</td>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3/22/F</td>
<td>ENT</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/70/M</td>
<td>ENT, kidney, skin</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5/68/F</td>
<td>ENT</td>
<td>5</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6/41/F</td>
<td>ENT, pulmonary</td>
<td>9</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>MMF and prednisolone</td>
<td></td>
</tr>
<tr>
<td>7/29/F</td>
<td>ENT</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8/58/M</td>
<td>ENT, skin, kidney, PNS</td>
<td>17</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>MMF and prednisolone</td>
<td></td>
</tr>
<tr>
<td>9/42/F</td>
<td>ENT, pulmonary</td>
<td>14</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>prednisolone</td>
<td></td>
</tr>
<tr>
<td>10736/F</td>
<td>ENT, pulmonary</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AZA: azathioprine; CYC: cyclophosphamide; ENT: Ear, nose and throat; MMF: mycophenolate mofetil; RTX: rituximab; PNS: peripheral nerve system; F: female; M: male.

Table II. Presenting symptoms, visual acuity, computerised tomography before and after treatment, and subjective improvement.

<table>
<thead>
<tr>
<th>Pt. No</th>
<th>Presenting ophthalmological symptoms</th>
<th>Visual acuity right eye Before-after treatment</th>
<th>Visual acuity left eye Before-after treatment</th>
<th>CT findings right orbit</th>
<th>CT findings left orbit</th>
<th>Orbital mass size on CT after treatment right/left orbit</th>
<th>Subjective improvement reported by patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Right eye: pressure feeling over the eye</td>
<td>6/18–6/6</td>
<td>6/12–6/12</td>
<td>medial granuloma</td>
<td>normal</td>
<td>UC/UC</td>
<td>yes</td>
</tr>
<tr>
<td>2</td>
<td>Left eye: palpable tumour in the medial canthus, swollen and red eye lid</td>
<td>6/9–6/9</td>
<td>6/6–6/6</td>
<td>normal</td>
<td>medial granuloma</td>
<td>UC/UC/Regression</td>
<td>yes</td>
</tr>
<tr>
<td>3</td>
<td>Right eye: change in the perception of colour, two errors on Ishihara colour plates</td>
<td>6/6–6/6</td>
<td>6/6–6/6</td>
<td>apical granuloma</td>
<td>normal</td>
<td>Regression/UC</td>
<td>yes</td>
</tr>
<tr>
<td>4</td>
<td>Left eye: impaired motility, double vision</td>
<td>6/9–6/6</td>
<td>6/12–6/9</td>
<td>intra+extra conal granuloma</td>
<td>intra+extra conal granuloma</td>
<td>UC/UC</td>
<td>yes</td>
</tr>
<tr>
<td>5</td>
<td>Right eye: pressure feeling behind the eye</td>
<td>6/6–6/6</td>
<td>CF-CF</td>
<td>intra+extra conal granuloma</td>
<td>normal</td>
<td>UC/UC</td>
<td>yes</td>
</tr>
<tr>
<td>6</td>
<td>Right eye: pain in the medial canthus, change in the perception of colour</td>
<td>6/9–6/6</td>
<td>6/9–6/6</td>
<td>medial granuloma</td>
<td>medial granuloma</td>
<td>UC/UC</td>
<td>yes</td>
</tr>
<tr>
<td>7</td>
<td>Pain behind the eyes</td>
<td>6/9–6/6</td>
<td>6/36–6/18</td>
<td>intra+extra conal granuloma</td>
<td>intra+extra conal granuloma</td>
<td>UC/UC</td>
<td>yes</td>
</tr>
<tr>
<td>8</td>
<td>Left eye: oedema in the medial canthus</td>
<td>exenterated orbit</td>
<td>6/6–6/6</td>
<td>exenterated orbit before rituximab</td>
<td>intra+extra conal granuloma</td>
<td>+/-UC</td>
<td>yes</td>
</tr>
<tr>
<td>9</td>
<td>Right eye: pain in the orbit</td>
<td>6/6–6/4.5</td>
<td>6/6–6/6</td>
<td>apical granuloma</td>
<td>normal</td>
<td>UC/UC</td>
<td>yes</td>
</tr>
<tr>
<td>10</td>
<td>Epiphora, palpable tumour</td>
<td>6/6–6/6</td>
<td>6/6–6/6</td>
<td>normal</td>
<td>medial granuloma</td>
<td>UC/UC</td>
<td>no</td>
</tr>
</tbody>
</table>

UC: unchanged; CF: counting fingers.

criterion. All patients were proteinase-3 ANCA positive at the time of diagnosis. Previous organ manifestations of WG experienced by the patients are summarised in Table I. The median time from diagnosis of WG to the demonstration of orbital inflammation was 9.5 years (range: 2–23 years). Three patients had been treated for orbital inflammation prior to the study. All of these patients had received anti-tumour-necrosis factor-alpha antibody therapy, and one patient had also received cyclophosphamide on this indication. These patients were regarded as refractory with respect to the orbital inflammatory disease. Patient no. 7 had received rituximab due to active pulmonary and cutaneous vasculitis one year before the current study. None of the patients presented with clinical, radiological, or laboratory findings indicating active WG outside the orbits at study baseline. Rituximab (Mabthera, Roche, Basel, Switzerland) was given as 2 intravenous doses of 1000 mg, administered at days 1 and 14 of the study. Adjuvant medication given immediately before the infusions included anti-histamines and 100 mg of prednisolone. A second CT-scan of the orbits was performed 6 months after therapy.

Results

Symptoms at study baseline included pain and pressure sensation in the or-
Treatment of orbital inflammation with RTX in WG / B. Baslund et al.

bit, change in the perception of colour, double vision and epiphora. Objective findings included palpable tumour in the orbit (through the lids), oedema of the eye lids, mild protrusion of the eye globe, decreased visual acuity, errors on Ishiharas colour plates, impaired eye mobility, papil oedema, chronic nasal crusting and chronic nasal Staphylococcus aureus infection.

All patients tolerated rituximab treatment well, and serious side-effects, including macular oedema (11), were not observed. The peripheral CD20+ B cells were depleted in all cases for at least 6 months. The observed subjective and objective effects of rituximab therapy are listed in Table II. Nine out of ten patients reported subjective improvement that was sustained through-out the follow-up period (median duration of follow-up: 17 months [range: 6–18 months]). Four patients had impaired visual acuity at study baseline. Rituximab-treatment improved the visual acuity in all of these patients. (Table II). Patient no. 9 developed right-sided cataract and the visual acuity decreased to 6/12. However, it returned to 6/4.5 after cataract surgery.

At the time of the control CT-scan, progression of the orbital mass was halted in all cases, and size reduction was observed in two patients (Fig. 1). In one of the patients who did not obtain size-reduction of the orbital mass, a biopsy of the mass was performed 11 months after treatment at a time when no CD20+ B cells could be seen in the peripheral blood. This biopsy showed the presence of both B- and T-cells in the lesion.

Eight patients had chronic nasal infection with Staphylococcus aureus and nasal crusts. There was no association between the location of orbital inflammation and the location of nasal crusting.

Discussion

In this case-series study, we found that depletion of CD20+ B cells is frequently beneficial in WG patients with orbital inflammation. However, a radiological size-reduction of the orbital mass was seen in only 20% of cases. Of note, we did not observe size progression of the orbital mass in any of our patients. These results are in contrast with the observations by Aries et al. (9), who observed a further enlargement of the orbital mass in 3 out of 5 rituximab-treated WG patients with orbital inflammation. Although Aries and co-workers used a different scheme for rituximab treatment (4 infusions of 375 mg/m² in 4 weekly intervals), this unlikely explains the differences in outcome, since both regimes resulted in depletion of peripheral CD20+ B cells.

In a recent study, Taylor and co-workers used rituximab for the treatment of 10 patients with refractory ophthalmic manifestations of WG (8). The results of that study are comparable to our findings with regard to clinical efficacy of rituximab therapy.

The pathogenesis of orbital inflammation is unknown. The proximity of the nose and the orbit could suggest a “rhinnogenic” element in the pathogenetic events leading to orbital granuloma formation in WG. However, our observations do not support this hypothesis. The granulomatous lesions in WG consist of monocytes, macrophages, giant cells and neutrophils together with T-cells and B-cells (12). The inflammatory process induces orbital contracture in some patients, probably due to inflammation-provoked fibrosis. This condition is characterised by enophthalmos, restrictive ophthalmopathy, chronic orbital pain, and optic nerve disease and is not responsive to immunosuppressive treatment (13). Talar-Williams et al. reported orbital contracture in 6 out of 18 patients with orbital manifestations of WG. We did not observe this phenomenon in any of our patients, and to some extent this may account for the relatively high response rate to rituximab therapy in the cohort.

In conclusion, although available results are conflicting, our data suggest that rituximab treatment constitutes a therapeutic option for patients with WG and orbital inflammation.

Fig. 1. Computerised tomography (CT) findings in patient no. 2 before (A) and six months after (B) treatment with Rituximab. Note that the size of the tumour (*) in the left medial orbit decreased after treatment. The CT image at 6 months after the treatment (B) is slightly oblique, causing the levels of images A and B to be directly comparable only at the left side.
References


